We propose to work cooperatively with other investigators funded by this U24 mechanism to evaluate proteomic technologies that will enable the early detection of several tumor types through the application of blood-based tests. Our group, consisting of scientists at LBNL, UCSF, The Buck Institute, MD Anderson Hospital, and the University of British Columbia, has the broad expertise that this project requires. We will focus on breast cancer. Initially, we will examine both global strategies and targeted mass spectrometry (MS)-based approaches to develop optimal workflows for the identification of protein signatures of human breast cancer cells in murine plasma. The global strategies will utilize multiple workflows that emphasize quantitative comparisons. The targeted approaches will focus on cancer-specific proteins that result from aberrant RNA splicing. Candidate biomarkers will be validated using reverse phase protein arrays. The requisite antibodies will be generated by Epitomics. The next phase of the project will employ human clinical samples. Specifically, we will apply an analogous, optimized approach for analyzing plasma samples that will be prospectively collected from breast cancer patients (n = 200). Control samples will be obtained from healthy women with benign breast disease and from women with rheumatoid arthritis to account for the contribution of proteins associated with inflammatory processes. Our candidate approach targets both the spliceome, which will be profiled using breast cancer biopsies from the plasma donors, and posttranslational modifications (e.g., glycosylation, phosphorylation, proteolysis and oxidative damage). We also include a plan for establishing a systematic way to standardize proteomic protocols and data analysis among the groups that exploits curability to analyze mass spectra generated on numerous platforms and the robust statistical methods we will employ to mine these large data sets. Several other elements of the RFA are also addressed. For example, we summarize the analysis capacity of our instruments and our strategy for sharing project-generated resources including biological specimens, protocols, data, software tools, and intellectual resources. In the end, we envision that our group, in conjunction with the other CPTAC teams and the NCI, will develop methods, tools and reference samples for the research community that will make the promise of MS-based cancer biomarker discovery a reality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA126477-07
Application #
8145670
Study Section
Special Emphasis Panel (ZCA1-SRRB-C (O1))
Program Officer
Rodriguez, Henry
Project Start
2006-09-28
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2011
Total Cost
$1,091,701
Indirect Cost
Name
University of California San Francisco
Department
Anatomy/Cell Biology
Type
Schools of Dentistry
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Korkola, James E; Collisson, Eric A; Heiser, Laura et al. (2015) Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 10:e0133219
Guo, H; Gao, M; Lu, Y et al. (2014) Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene 33:3463-72
Zawadzka, Anna M; Schilling, Birgit; Cusack, Michael P et al. (2014) Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics 13:1034-49
Zawadzka, Anna M; Schilling, Birgit; Held, Jason M et al. (2014) Variation and quantification among a target set of phosphopeptides in human plasma by multiple reaction monitoring and SWATH-MS2 data-independent acquisition. Electrophoresis 35:3487-97
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Iacovides, Demetris C; Johnson, Aimee B; Wang, Nick et al. (2013) Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol Cell Proteomics 12:3210-20
Drake, Penelope; Schilling, Birgit; Gibson, Brad et al. (2013) Elucidation of N-glycosites within human plasma glycoproteins for cancer biomarker discovery. Methods Mol Biol 951:307-22
Wang, Daojing; Huang, Jing; Hu, Zhi (2012) RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics 11:M111.011932
Witkowska, H Ewa; Hall, Steven C; Fisher, Susan J (2012) Breaking the bottleneck in the protein biomarker pipeline. Clin Chem 58:321-3
Ma, Ze-Qiang; Polzin, Kenneth O; Dasari, Surendra et al. (2012) QuaMeter: multivendor performance metrics for LC-MS/MS proteomics instrumentation. Anal Chem 84:5845-50

Showing the most recent 10 out of 33 publications